Introduction

    Santolecan Pharmaceuticals Limited Liability Company is a US-based startup company that focuses on discovery of innovative therapeutics to improve human health and help patients live a quality of life. Our company project was awarded 3rd place in the 2022 Harvard University “H-InnoPitch” International Start-Up Pitch Competition and 2nd place in the 2024 International Innovation Contest for Startup Entrepreneurs (Ranked 7th out of 1,400 projects worldwide), and the success of our drug candidate projects can benefit millions of patients. Currently, our pan-RAS candidate CQ-0736 has demonstrated superior efficacy compared to RMC-6236 (Rasonque), while also overcoming acquired resistance to RMC-6236 in preclinical CDX and PDX models. CQ-0736 was also selected for an oral presentation at the American Association for Cancer Research Annual Meeting 2026, where only about 20~30 drug development pipelines were chosen from over 7,400 abstracts.